Rice Hall James & Associates LLC Sells 82,427 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Rice Hall James & Associates LLC lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,081,316 shares of the biotechnology company’s stock after selling 82,427 shares during the quarter. Rice Hall James & Associates LLC owned 1.00% of BioCryst Pharmaceuticals worth $15,651,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $46,000. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. increased its stake in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. KBC Group NV increased its stake in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at $82,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $9.05 on Tuesday. The company’s 50-day moving average is $7.89 and its 200 day moving average is $7.79. The company has a market capitalization of $1.87 billion, a P/E ratio of -14.84 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.11.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BCRX. Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC upped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.